Use of CroFab® antivenin in the management of a very young pediatric copperhead envenomation

Trinh, Hai H.; Hack, Jason B.

doi:10.1016/j.jemermed.2005.02.005

Cited by 10 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The only other pediatric data available on CroFab use has been from a few case reports (one patient for each of three case reports), which are unique by nature and do not necessarily represent typical pediatric envenomations. [6][7][8] Overall, limited information is available concerning the treatment of children with CroFab.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations

Pizon¹,

Riley²,

LoVecchio³

et al. 2007

Acad Emergency Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations

Pizon¹,

Riley²,

LoVecchio³

et al. 2007

Acad Emergency Med

View full text Add to dashboard Cite

show abstract

“…Antivenom has been shown to be safe to use in pediatric and infant populations. 93,[111][112][113][114][115] (Recommendation grade: 1B) ALLERGIC OR ANAPHYLACTIC REACTIONS Antivenom-induced hypersensitivity reactions and serum sickness occur in approximately 8% and 13%, respectively, of patients treated with FabAV. 116 Some can be severe, and providers should be prepared to treat with epinephrine, steroids, antihistamines, or emergency airway management.…”

Section: Pregnant Womenmentioning

confidence: 99%

Wilderness Medical Society Practice Guidelines for the Treatment of Pitviper Envenomations in the United States and Canada

Kanaan

Ray

Stewart

et al. 2015

Wilderness & Environmental Medicine

View full text Add to dashboard Cite

“…3,7,16,21,22,30 Before 2010, most published reports of successful use of antivenom for copperhead envenomations were case reports. 9,31,32 Increased provider education may lead to increased use of antivenom for copperhead bites, which may lead to decreased use of narcotic pain medication and improved return of limb function.…”

Section: Discussionmentioning

confidence: 99%

No Change in the Use of Antivenom in Copperhead Snakebites in Ohio

Plash

Stolz

Goertemoeller

et al. 2021

Wilderness & Environmental Medicine

View full text Add to dashboard Cite

Introduction-Historically, copperhead snake (Agkistrodon contortrix) envenomations were not treated with antivenom owing to related adverse events and little benefit. However, recent studies have shown improved outcomes with antivenom use. We hypothesized that the frequency of antivenom use for copperhead envenomation in Ohio has increased as benefits of administration became more widely known.Methods-All copperhead snakebites reported to the Ohio poison control centers from 2006 through 2016 were compiled. Antivenom use, bite severity, and disposition were abstracted. A nonparametric test for trend was used to evaluate changes over time for the number of patients treated with antivenom and patient disposition. Logistic regression was used to assess the odds of admission vs discharge with antivenom administration, bite severity, age, and sex as independent variables.Results-Ninety-eight patients reported copperhead snakebites to the poison control centers. The test of trend showed no change in the proportion of patients treated with antivenom by year (P=0.42). There was no difference in the proportion of patients discharged home (P=0.38) per year. Logistic regression showed antivenom use was associated with an odds ratio for admission of 46.7 (95% CI: 7.3-296.4).Conclusions-The frequency of antivenom use for copperhead bites did not significantly increase between 2006 and 2016. Administration of antivenom was associated with a large increase in the odds of admission to the hospital, even when controlling for bite severity. Further education regarding the benefits and safety of antivenom may increase its use for copperhead snakebites, but may lead to an increase in hospital admissions.

show abstract

Use of CroFab® antivenin in the management of a very young pediatric copperhead envenomation

Cited by 10 publications

References 16 publications

Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations

Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations

Wilderness Medical Society Practice Guidelines for the Treatment of Pitviper Envenomations in the United States and Canada

No Change in the Use of Antivenom in Copperhead Snakebites in Ohio

Contact Info

Product

Resources

About